TY - JOUR T1 - Peri- and Post-natal Risk Factors Associated with Health of Newborns JF - medRxiv DO - 10.1101/2023.01.12.23284503 SP - 2023.01.12.23284503 AU - Yanan Long AU - Atif Khan AU - Andrey Rzhetsky Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/14/2023.01.12.23284503.abstract N2 - Designing prophylactic strategies for newborns requires understanding of the factors that contribute to immunity and resistance to infection. We analyzed 1,892,035 mother-newborn pairs in which both the mother and newborn were observed continuously for at least one year before and after birth. As part of this study, we considered maternal exposures to infections and immune disorders during pregnancy, exposures to anti-infection medications by both mother and newborn, as well as the newborn’s delivery type and reported complications. According to our analyses, infection rates and immune disorder rates were over-dispersed among newborns. The most consequential factors predicting newborns’ immune health were preterm birth, with 276.3% and 193.9% odds ratio increases for newborn bacterial infections. Broadly speaking, newborn anti-infective prescriptions were associated with considerable increases in odds ratios of diseases affecting immune health, while maternal prescriptions were associated with fewer outcomes and with mixed signs. The Cesarean section mode of delivery, the mother’s age, the sex of the newborn, and the mother’s exposure to infections all showed significant but smaller effects on the newborn’s immune health. Female newborn appeared to be better protected against diseases with immune system etiology, except for miscellaneous infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the DARPA Big Mechanism program under ARO contract W911NF1410333, by National Institutes of Health grants R01HL122712, 1P50MH094267, and U01HL108634-01, and by a gift from Liz and Kent Dauten. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Chicago Institutional Review Boards determined that the study is IRB exempt, given that patient data in both countries were preexisting and de-identified.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe IBM MarketScan data is available by to licensed users. See https://www.ibm.com/products/marketscan-research-databases ER -